FDA Clears First Generic Proventil Inhaler

Cipla has received the FDA’s first approval for a generic Proventil HFA (albuterol sulfate) metered dose inhaler for treating or preventing bronchospasms in patients age four years and older with reversible obstructive airway disease.

The agency cited the importance of albuterol products during the COVID-19 crisis in its announcement of the approval. The 90mcg inhaler also received clearance for preventing exercise-induced bronchospasms in the same age group.

“The FDA recognizes the increased demand for albuterol products during the novel coronavirus pandemic,” said FDA Commissioner Stephen Hahn.